Skip to main content
SpringerLink
Log in

Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy

  • Brief Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

To describe the frequency of head and/or pancreas uncinate process uptake of 99mTc-HYNIC-TOC, to study its nature, and analyze its diagnostic value.

Materials and methods

Retrospective evaluation of 47 consecutive 99mTc-HYNIC-TOC examinations was conducted. Head and/or pancreas uncinate process uptake was considered to be physiological in patients with normal CT at the same episode and in follow-up. It was analyzed if age or diabetes mellitus was justifying the existence or not of uptake.

Results

32.5% patients showed uptake; 73% of them were mild. 84.6% patients with uptake have no pathology and 4% had neuroendocrine pancreatic disease at CT. Neither the age nor the diabetes mellitus established differences in patients without lesion.

Conclusions

Near one-third of patients show physiological uptake by head and/or pancreas uncinate process at 99mTc-HYNIC-TOC scintigraphy. It seems that neither the diabetes nor the ages are factors that determine this physiological uptake.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bangard M, Béhé M, Bender H, Guhlke S, Willkomm P, Risse J, et al. Technetium-99m-octreotide for the detection of somatostatin receptor positive (SSTR+) tumors: preliminary results [abstract]. Eur J Nucl Med. 1998;25:837.

    Article  Google Scholar 

  2. Bangard M, Behe M, Guhlke S, Otte R, Bender H, Maecke HR, et al. Detection of somatostatin receptor-positive tumours using the new [99mTc]-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111 in-DTPA-D-Phe1-octreotide. Eur J Nucl Med. 2000;27:628–37.

    Article  CAS  PubMed  Google Scholar 

  3. Hubalewska-Dydejczyk A, Fröss-Baron K, Mikołajczak R, Maecke HR, Huszno B, Pach D, et al. [99mTc]-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years experience. Eur J Nucl Med Mol Imaging. 2006;33:1123–33.

    Article  CAS  PubMed  Google Scholar 

  4. Kunikowska J, Królicki L, Pawlak D, Zerizer I, Mikołajczak R. Semiquantitative analysis and characterization of physiological biodistribution of (68) Ga-DOTA-TATE PET/CT. Clin Nucl Med. 2012;37:1052–7.

    Article  PubMed  Google Scholar 

  5. Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls and pitfalls in interpretation. RadioGraphics. 2015;35:500–16.

    Article  PubMed  Google Scholar 

  6. Mapelli P, Tam HH, Sharma R, Aboagye EO, Al-Nahhas A. Frequency and significance of physiological versus pathological uptake of 68Ga-DOTATATE in the pancreas: validation with morphological imaging. Nucl Med Commun. 2014;35:613–9.

    Article  CAS  PubMed  Google Scholar 

  7. Krausz Y, Rubinstein R, Appelbaum L, Mishani E, Orevi M, Fraenkel M, et al. Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patterns. Clin Nucl Med. 2012;37:57–62.

    Article  PubMed  Google Scholar 

  8. Castellucci P, Ucha JP, Fuccio C, Rubello D, Ambrosini V, Montini GC, et al. Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT. J Nucl Med. 2011;52:886–90.

    Article  PubMed  Google Scholar 

  9. Jacobsson H, Larsson P, Jonsson C, Jussing E, Grybäck P. Normal uptake of 68Ga-DOTA-TOC by the pancreas uncinate process mimicking malignancy at somatostatin receptor PET. Clin Nucl Med. 2012;37:362–5.

    Article  PubMed  Google Scholar 

  10. Chondrogiannis S, Grassetto G, Marzola MC, Rampin L, Massaro A, Bellan E, et al. 18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours. Nucl Med Commun. 2012;33:179–84.

    Article  CAS  PubMed  Google Scholar 

  11. Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004–10.

    Article  PubMed  Google Scholar 

  12. Yamaga LY, Neto GC, da Cunha ML, Osawa A, Oliveira JC, Fonseca RQ, et al. [99mTc]-HYNIC-TOC increased uptake can mimic malignancy in the pancreas uncinate process at somatostatin receptor SPECT/CT. Radiol Med. 2016;121:225–8.

    Article  PubMed  Google Scholar 

  13. Koçyiğit Deveci E, Ocak M, Bozkurt MF, Türker S, Kabasakal L, Uğur O. The diagnostic efficiency of 99mTc-EDDA/HYNIC-Octreotate SPECT-CT in comparison with 111 in-pentetrotide in the detection of neuroendocrine tumours. Mol Imaging Radionucl Ther. 2013;22:76–84.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Watfah Rychlinski C, Mather SJ, et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111 in-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med. 2003;44:708–16.

    CAS  PubMed  Google Scholar 

  15. Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: monodose evaluation and comparison with 111 in-octreotide. J Nucl Med. 2000;41:114–9.

    Google Scholar 

  16. Sako T, Hasegawa K, Nishimura M, Kanayama Y, Wada Y, Hayashinaka E, et al. Positron emission tomography study on pancreatic somatostatin receptors in normal and diabetic rats with 68Ga-DOTA-octreotide: a potential PET tracer for beta cell mass measurement. Biochem Biophys Res Commun. 2013;442:79–84.

    Article  CAS  PubMed  Google Scholar 

  17. Krenning EP, de Jong M, Kooij PPM, Breeman WAP, Bakker WH, de Herder WW, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10:S23–9.

    Article  PubMed  Google Scholar 

  18. Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Oberg KE1, Reubi JC, Kwekkeboom DJ, Krenning EP. Gastroenterology. 2010;139:742–53.

    Article  PubMed  Google Scholar 

  19. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157–98.

    Article  CAS  PubMed  Google Scholar 

  20. Unger N, Ueberberg B, Schulz S, Saeger W, Mann K, Petersenn S. Differential expression of somatostatin receptor subtype 1-5 proteins in numerous normal human tissues. Exp Clin Endocrinol Diabetes. 2012;120:482–9.

    Article  CAS  PubMed  Google Scholar 

  21. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes of radiotracers selected for scintigraphic and radiotherapeutic somatostatin SST1-SST5 use. Eur J Nucl Med. 2000;27:273–82.

    Article  CAS  PubMed  Google Scholar 

  22. Kunikowska J, Królicki L. PET receptor imaging in clinical oncology. Nucl Med Rev. 2012;15:C61–3.

    Article  Google Scholar 

  23. Gandomkar M, Najafi R, Rabbani M. 99mTc-EDDA-Tricine-HYNIC-TOC versus 99mTc-EDDA-Tricine-HYNIC-TATE: synthesis and monodose result of two new radiopharmaceuticals for somatostatin receptor scintigraphy. International Atomic Energy Agency, Division of Physical and Chemical Sciences and Division of Human Health, Vienna (Austria); 2005. p. 348, 180; ISTR-2005: International symposium on trends in radiopharmaceuticals; Vienna (Austria); 14–18 Nov 2005; IAEA-CN-130; IAEA-CN-130/096P.

  24. Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine. 2012;42:80–7.

    Article  CAS  PubMed  Google Scholar 

  25. O’Sullivan AW, Heaton N, Rela M. Cancer of the uncinate process of the pancreas: surgical anatomy and clinicopathological features. Hepatobiliary Pancreat Dis Int. 2009; 8(6):569–74.

  26. Gersell DJ, Gingerich RL, Greider MH. Regional distribution and concentration of pancreatic polypeptide in the human and canine pancreas. Diabetes. 1979;28:11–5.

    Article  CAS  PubMed  Google Scholar 

  27. Portela-Gomes GM, Stridsberg M, Grimelius L, Oberg K, Janson ET. Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. Appl Immunohistochem Mol Morphol. 2000;8:126–32.

    CAS  PubMed  Google Scholar 

  28. Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, et al. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological and pathological processes in PET/CT uptake. Eur J Nucl Med Mol Imaging. 2013;40:514–23.

    Article  CAS  PubMed  Google Scholar 

  29. Prasad V, Baum PR. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumour lesions. Q J Nucl Med Mol Imaging. 2010;54:61–7.

    CAS  PubMed  Google Scholar 

  30. Barbieri F, Bajetto A, Pattarozzi A, Gatti M, Würth R, Thellung S, et al. Peptide receptor targeting in cancer: the somatostatin paradigm. Int J Pept. 2013;2013:926295. doi:10.1155/2013/926295.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Department, University Hospital Miguel Servet, Paseo Isabel la Católica 1-3, 50009, Zaragoza, Spain

    L. de la Cueva, P. Lloro, M. J. Sangrós, P. Navarro, S. Álvarez & D. Abós

  2. Clínica las Américas, Medellín, Colombia

    L. López Vélez

  3. Radiology Department, University Hospital Miguel Servet, Zaragoza, Spain

    L. Sarria

Authors
  1. L. de la Cueva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Lloro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. J. Sangrós
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. López Vélez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Navarro
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L. Sarria
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Álvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. Abós
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. de la Cueva.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Complete anonymity has been preserved for all individual participants; informed consent has been obtained before any study with ionizante radiation.

Statement of human rights

For this type of study, formal consent is not required.

Statement on the welfare of animals

This article does not contain any studies with animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

de la Cueva, L., Lloro, P., Sangrós, M.J. et al. Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy. Clin Transl Oncol 19, 915–920 (2017). https://doi.org/10.1007/s12094-017-1616-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-017-1616-3

Keywords

Search

Navigation